Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma

ConclusionDaratumumab monotherapy has significant activity and good tolerance in heavily pretreated RRMM patients.
Source: Advances in Medical Sciences - Category: Biomedical Science Source Type: research